NVision Imaging, a Ulm, Germany-based developer of MRI polarizers and hyperpolarized imaging agents, raised $30M in Series A funding, with an additional $19.5M in funding from the German Government.
The round, which brought the total amount to $35M, not including the government funds, was led by Playground Global, with participation from return investors b-to-v and new participation from Pathena Investments, Entree Capital, Lauder Family, ES Kapital, and Sparkassenkapital Ulm.
The company intends to use the funds to advance its development and deployment efforts.
Led by CEO Dr. Sella Brosh, NVision is a developer of MRI polarizers and hyperpolarized imaging agents. Its hyperpolarization technology permits the assessment of human and animal metabolism by standard MRI, enabling advanced preclinical and clinical applications, including novel cancer diagnosis and monitoring of response to therapy.
The company has a partnership already in place with Siemens Healthineers, a provider of MRI technology, plans to deploy systems at over 50 of the world’s top cancer centers by 2025, and a signed collaboration with Memorial Sloan Kettering.
FinSMEs
23/06/2023